trastuzumab-anns Kanjinti
Selected indexed studies
- Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US. (Ther Adv Med Oncol, 2021) [PMID:35003333]
- Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union. (Future Oncol, 2024) [PMID:38305004]
- Comparative cost savings of biosimilar and dose rounding utilization in oncology care. (J Oncol Pharm Pract, 2023) [PMID:36259235]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database. (2025) pubmed
- Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US. (2021) pubmed
- Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union. (2024) pubmed
- Comparative cost savings of biosimilar and dose rounding utilization in oncology care. (2023) pubmed
- Pulmonary Hypertension Following the Use of Trastuzumab Biosimilars. (2026) pubmed
- Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States. (2024) pubmed
- Effectiveness and safety of trastuzumab-anns compared to reference trastuzumab among patients with HER2-positive breast cancer: A non-inferiority study. (2026) pubmed